Epidemiology and social
Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load
Baggaley, Rebecca Fa; Griffin, Jamie Ta; Chapman, Ruthb; Hollingsworth, T Déirdrea; Nagot, Nicolasc; Delany, Sineadd; Mayaud, Philippee; de Wolf, Frankf; Fraser, Christophea; Ghani, Azra Ca; Weiss, Helen Ab
aMRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, UK
bInfectious Disease Epidemiology Unit, Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
cUniversité Montpellier 1, EA 4205 Transmission, Pathogenese et Prevention de l'infection par le VIH, CHU Montpellier, Montpellier, France
dReproductive Health and HIV Research Unit, University of Witwatersrand, Johannesburg, Republic of South Africa
eClinical Research Unit, Department of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK
fHIV Monitoring Foundation, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Received 27 November, 2008
Revised 3 February, 2009
Accepted 13 February, 2009
Correspondence to Dr Rebecca Baggaley, Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College London, St Mary's Campus, Norfolk Place, London W2 1PG, UK. Tel: +44 207 5943288; e-mail: firstname.lastname@example.org
Objective: Trials of herpes simplex virus (HSV) suppressive therapy among HSV-2/HIV-1-infected individuals have reported an impact on plasma HIV-1 viral loads (PVLs). Our aim was to estimate the population-level impact of suppressive therapy on female-to-male HIV-1 sexual transmission.
Design and methods: By comparing prerandomization and postrandomization individual-level PVL data from the first two HSV suppressive therapy randomized controlled trials in sub-Saharan Africa, we estimated the effect of treatment on duration of asymptomatic infection and number of HIV-1 transmission events for each trial.
Results: Assuming that a reduction in PVL is accompanied by an increased duration of HIV-1 asymptomatic infection, 4–6 years of HSV suppressive therapy produce a 1-year increase in the duration of this stage. To avert one HIV-1 transmission requires 8.8 [95% confidence interval (CI), 5.9–14.9] and 11.4 (95% CI, 7.8–27.5) women to be treated from halfway through their HIV-1 asymptomatic period, using results from Burkina Faso and South African trials, respectively. Regardless of the timing of treatment initiation, 51.6 (95% CI, 30.4–137.0) and 66.5 (95% CI, 36.7–222.6) treatment-years are required to avert one HIV-1 infection. Distributions of set-point PVL values from sub-Saharan African populations suggest that unintended adverse consequences of therapy at the population level (i.e. increased HIV-1 transmission due to increased duration of infection) are unlikely to occur in these settings.
Conclusion: HSV suppressive therapy may avert relatively few HIV-1 transmission events per person-year of treatment. Its use as a prevention intervention may be limited; however, further research into its effect on rate of CD4 cell count decline and the impact of higher dosing schedules is warranted.
Epidemiological and biological evidences show that herpes simplex virus type 2 (HSV-2) infection enhances acquisition of HIV-1 and may also increase levels of genital and plasma HIV-1 RNA within coinfected individuals and hence increase transmission of HIV-1 in populations [1–6]. It is, therefore, reasonable to assume that HSV suppressive therapy may reduce transmission of HIV-1 in populations with high prevalence of both viruses .
Recent randomized placebo-controlled trials (RCTs) have quantified the effect of HSV suppressive therapy on the HIV-1 infectiousness of dually HSV-2/HIV-1 positive individuals [8–15]. The first two trials from sub-Saharan Africa reporting the effect of 3-month HSV suppressive therapy on plasma HIV-1 viral loads (PVLs) were parallel-arm RCTs among dually HIV-1/HSV-2 seropositive women ineligible for HAART in Burkina Faso (n = 140 ) and South Africa (n = 300 ). Both reported significant reductions in mean PVL [0.53 log10 copies/ml, 95% confidence interval (CI), 0.35–0.72 using valacylovir 500 mg twice daily (b.i.d.)  and 0.34 log10 copies/ml, 95% CI, 0.15–0.54 using acyclovir 400 mg b.i.d. ]. These trials also reported significant reductions in genital HIV-1 and HSV-2 shedding frequency and viral loads [8,9]. Three cross-over trials involving intense follow-up of male and female participants in Peru and Thailand and using valacyclovir or high dose acyclovir (800 mg b.i.d.) also reported significant reductions in PVL (0.26 log10 copies/ml, 95% CI, 0.19–0.33 ; 0.43 log10 copies/ml, 95% CI, 0.29–0.56 ; and 0.33 log10 copies/ml, 95% CI, 0.23–0.42 ) as well as significant reductions in rectal and cervicovaginal HIV-1 RNA concentrations [13–15].
By reducing both genital and plasma HIV-1 viral loads, HSV suppressive therapy is likely to reduce infectiousness of HIV-1, as PVL is highly correlated with risk of HIV-1 transmission [16,17]. In addition, reduced PVL may increase life expectancy by decreasing the rate of CD4 cell count decline during the asymptomatic period of HIV-1 infection [18,19], thus delaying the point at which HAART should be initiated. However, this reduced infectiousness may be offset by an increased duration of infection, providing more opportunity for transmission, although at a lower rate. In this study, we translate results of the first two African HSV therapy trials [8,9] into number of potential HIV-1 infections averted by HSV suppressive therapy.
We assessed the population-level impact of HSV suppressive therapy on HIV-1 transmission by estimating the transmission potential of each HIV-1-infected individual as described by Fraser et al. . For the asymptomatic period of HIV-1 infection, the transmission potential is defined as the product of infectiousness and the duration of asymptomatic infection, that is, the mean number of persons that one index case can infect over their whole asymptomatic period, estimated as a function of set-point PVL (defined as the PVL steady state reached after the peak PVL in early infection and before progression to AIDS).
The concepts we explore are illustrated in Fig. 1 that shows duration of asymptomatic HIV-1 infection, HIV-1 transmission rate and HIV-1 transmission potential against set-point PVL (using functions reported by Fraser et al. ) and changes in these properties for two illustrative HIV-1-infected individuals when they start HSV suppressive therapy. At some point during asymptomatic infection, therapy may be initiated and, we hypothesize, be accompanied by a drop in set-point PVL (Fig. 1a). We assume that this drop increases each individual's projected duration of infection (Fig. 1b) and decreases their infectiousness (Fig. 1c). We further assume that HSV-2 infection always precedes HIV-1 infection, as a simplifying assumption and to estimate maximum impact of HSV suppressive therapy. Figure 1d illustrates that the combined effect on transmission potential (i.e. number of onward HIV-1 transmission events over each individual's asymptomatic period) depends on their original set-point PVL. The impact on individuals with high set-point PVL is to increase transmission potential, whereas the opposite is true for those with lower set-point PVL. Therefore, the public health impact of interventions reducing PVL by a moderate amount depends on the distribution of set-point PVL within the population.
Plasma HIV-1 viral load data
There are limited data linking viral load measures to HIV-1 infectiousness. Although a focus of the two African trials was the impact of therapy on genital HIV-1 RNA, to our knowledge, there are no data that quantify the risk of ongoing HIV-1 transmission by frequency or quantity of genital HIV-1 RNA for female-to-male HIV-1 transmission. Therefore we used PVL data rather than genital viral load to estimate infectiousness.
We used data on PVL preintervention and postintervention from the Burkina Faso and South African trials [8,9] to estimate the potential change in infectiousness and change in duration of asymptomatic infection that each woman may experience if started on indefinite HSV therapy. This analysis is restricted to participants with a measurement available from the end of the study period (12 weeks). Details of the laboratory methods used for quantifying PVL for each study are provided as Supplementary Digital Content (see document and figures, Supplemental Digital Content 1, 2 and 3).
Quantifying reduction in plasma HIV-1 viral loads with herpes simplex virus suppressive therapy
We examined individual-level data from the two trials to investigate whether the reduction in PVL varied with prerandomization (baseline) PVL. Two and three prerandomization PVL measurements were taken from study participants in South Africa and Burkina Faso, respectively. For purposes of comparison between studies, we used the baseline measurement taken closest to the time of randomization. Those with undetectable PVL were assigned a value of half the detection threshold of the assay (detection thresholds of 300 and 50 HIV-1 RNA copies/ml for Burkina Faso and South Africa, respectively). Analysing changes in PVL in the two trials suggested a reduction in PVL among treated participants for all levels of baseline PVL recorded (except very low levels, <3.0 log10 copies/ml, in which any further reduction in PVL is unlikely to be detected) but no such decrease among controls (see document and figures, Supplemental Digital Content 1, 2 and 3). Therefore, we estimate the effect of suppressive therapy on HIV-1 transmission using data from the treatment arms only.
Translating plasma HIV-1 viral loads into estimates of infectiousness and duration of asymptomatic infection
We followed the approach taken by Fraser et al. . Briefly, the risk of HIV-1 transmission per year, stratified by PVL of the index case, is quantified using data from a Zambian cohort . To translate PVL data of each RCT participant, V, into an estimate of their infectiousness, defined as the transmission rate (number of HIV-1 transmission events per HIV-1-infected individual per year) β(V), the following logistic function is used:
where βmax, the maximum infection rate per annum, is 0.317 per year; β50, the PVL at which infectiousness is half its maximum, is 13 938 copies/ml and βk, the steepness of the increase in infectiousness as a function of PVL is 1.02.
A logistic function is also used to estimate the mean duration of the asymptomatic period of HIV-1 infection as a function of PVL using data from the Amsterdam Seroconverters Cohort and allows for variability in the duration, given set-point PVL . The Amsterdam Seroconverters Cohort prospectively recruited homosexual men from 1982 onwards; the cohort has been described elsewhere . The PVL of each RCT participant, V, is translated into an estimate of their duration of asymptomatic infection, D(V), using:
Equation (Uncited)Image Tools
where Dmax, the maximum duration of asymptomatic infection, is 25.4 years; D50, the PVL at which the duration is half its maximum, is 3058 copies/ml and Dk, the steepness of the decrease in duration as a function of PVL, is 0.41.
Calculating HIV-1 infections averted
Each intervention arm participant's transmission potential (number of transmission events during their entire duration of asymptomatic infection) was calculated as the product of their transmission rate and duration [from (Equations 1 and 2) ] for their baseline PVL and similarly for their PVL at the end of the trial. The number of infections averted is the difference between them. This assumes that suppressive therapy starts at the beginning of asymptomatic infection; therefore, alternative scenarios in which treatment starts at different points during the incubation period were also explored. A bootstrap sampling method was used to derive 95% confidence bounds for each outcome .
The number of study participants randomized to the intervention and control arms was 68 and 68 for Burkina Faso and 152 and 148 for South Africa, respectively. For the Burkina Faso (South Africa) trial, 62 (132) from the treatment and 63 (135) from the control arm had PVL measurements recorded at the end of the 3-month follow-up and were included in our analysis. For Burkina Faso, 61 intervention and 60 control arm participants had a baseline PVL measurement at the time point closest to randomization. The remaining four participants in the trial (one in treatment, three in control arms) had measurements recorded at 3 weeks prerandomization. For South Africa, one control arm participant with a PVL measurement at study end had no measurement at the time point closest to randomization; her measurement recorded at her previous baseline visit (1 week before) was used.
Figure 2 shows distribution of PVL among women in the Zambian study that links PVL to infectiousness (Fig. 2a, ), transmission potential by set-point PVL (Fig. 2b) and the distribution of PVL for study participants in the two African trials (Figs. 2c–f, [8,9]). The Zambian data show women only to make it comparable with the trials because there may be differences in PVL distributions between women and men [22,23]. This distribution is skewed because of the selection of nontransmitting partners for this discordant couple study. Burkina Faso study participants at baseline had a similar PVL distribution to those from Zambia (mean PVL 4.4 and 4.5 log10 copies/ml, respectively), whereas those from South Africa were slightly lower (mean 3.9 log10 copies/ml). However, both trials recorded more frequent undetectable PVL measurements than the Zambian study (Figs. 2a,c,e). This may partly be due to greater immunosuppression among the Zambian cohort [>80% of participants had CD4 cell count <400 cells/μl compared with a median 446 (range 334–628) cells/μl for Burkina Faso and 475 (251–1382) cells/μl for South Africa]. Figures 2d and f illustrate the shift in distribution of PVL for the treatment arms after 3 months, with no such shift apparent for the control arms (Figs. 2c and e). The highest frequency PVL group for the controls before and at study end is close to the level at which transmission potential is predicted to peak.
Impact of treatment on infection duration and transmission: results for study participants
Table 1 shows estimated benefits of HSV suppressive therapy based on the duration of asymptomatic infection in the two trial populations. Greater benefits are produced the earlier that therapy is initiated in HIV-1 infection. A maximum increase in duration of asymptomatic infection of 2.8 years using Burkina Faso data and 1.9 years using South African data was estimated if therapy was initiated at the beginning of asymptomatic infection. The duration of therapy required to gain one HAART-free year extension to the asymptomatic period was independent of time at which therapy was initiated and was estimated as 4.2 years (95% CI, 2.5–8.6) using Burkina Faso data and 6.2 years (95% CI, 3.4–14.6) using South African data.
Table 1 also shows the impact of HSV suppressive therapy on number of infections averted. Unless therapy was initiated very early in infection and continued throughout the asymptomatic period, that is, for more than a decade, relatively few HIV-1 infections could be averted per woman treated. To avert one HIV-1 transmission to a sexual partner of an HSV-treated woman requires 8.8 (95% CI, 5.9–14.9) and 11.4 (95% CI, 7.8–27.5) women to be treated from halfway through their HIV-1 asymptomatic period, predicted using Burkina Faso and South African data, respectively. If therapy can be initiated at the beginning of asymptomatic infection, these figures reduce to 4.4 (95% CI, 3.0–7.5) and 5.7 (95% CI, 3.9–13.8), respectively. There was a linear relationship between time on treatment and benefits achieved; therefore, regardless of the timing of treatment initiation, 51.6 (95% CI, 30.4–137.0) and 66.5 (95% CI, 36.7–222.6) treatment-years are required to avert one HIV-1 infection using Burkina Faso and South African data, respectively.
Impact of herpes simplex virus suppressive therapy on HIV-1 transmission: generalized results
Figure 3 illustrates the effect on number of onward HIV-1 transmission events if therapy was administered to a hypothetical population of 1000 HSV-2/HIV-1 dually seropositive individuals, by mean set-point PVL (assumed normal distribution, SD, n = 1) if the reduction in PVL through suppressive therapy was as predicted for Burkina Faso or South African trial data, respectively. All populations with a mean set-point PVL less than about 4.75 log10 copies/ml are likely to experience a net beneficial effect of an intervention such as this, which produces a modest reduction in PVL. Mean PVL for the trials' data and Zambian dataset, as well as data from Uganda for HSV-2-seropositive individuals , illustrates that HSV-2-infected populations in Africa are likely to have distributions in PVL that would result in a positive impact of HSV suppressive therapy. The largest relative benefit of HSV suppression would occur among populations with modestly low (around median 3.5 log10 copies/ml, Fig. 3) mean PVLs because it is at this point that changes in PVL have the greatest impact on transmission potential (shown by the steepest gradient of the curve in Fig. 2b).
Our analysis suggests that if HSV suppressive therapy reduces PVL of HIV-1/HSV-2-positive individuals as demonstrated by the first two African trials, it would reduce HIV-1 transmissions and increase the duration of asymptomatic HIV-1 infection, although by modest amounts. We estimate that treating between nine and 11 HSV-2/HIV-1-infected individuals, starting therapy halfway through asymptomatic HIV-1 infection, would avert one HIV-1 infection. This compares favourably with the impact of male circumcision, in which an estimated five to 15 surgeries would avert one HIV-1 infection over 10 years (UNAIDS/WHO/SACEMA Expert Group on Modelling the Impact and Cost of Male Circumcision for HIV Prevention manuscript in preparation). This is partly due to the use of suppressive therapy to prevent transmission rather than acquisition: there is no ‘wastage’ of the intervention on those who will never be exposed to HIV-1 (the effect of HSV suppressive therapy on reducing acquisition of HIV-1 among HSV-2-positive/HIV-1-negative women has recently been investigated by two RCTs but no effect was observed [25,26]). Results of the Partners in Prevention (PiP) study, following over 3400 HIV-1-discordant couples, will provide the first empirical data examining whether HSV suppressive therapy reduces HIV-1 transmission (www.clinicaltrials.gov NCT00194519).
Although time from HIV-1 acquisition to symptomatic infection is longer for individuals with lower PVL , an intervention decreasing PVL in order to increase the duration of asymptomatic infection has not been previously assessed. Historical studies  using high-dose acyclovir suggested moderate improvements in survival, although these typically treated patients with late stage rather than asymptomatic infection. The potential of HSV therapy to reduce the rate of CD4 cell count decline and thus increase the time before starting HAART has important implications for HIV-1 patient management. PiP may have sufficient power to detect such an effect, which is also currently being investigated in Rakai, Uganda (www.clinicaltrials.gov NCT00405821), although many study participants started therapy while already at relatively late stage infection. To investigate impact for early HIV-1 infections, an ancillary study  to the recent HPTN039 HSV suppressive therapy HIV-1 acquisition RCT is maintaining HIV-1 seroconverters on their trial regimens (acyclovir or placebo) to investigate whether treatment alters HIV-1 set-point up to 6 months.
In contrast to the positive results from the two trials used in this analysis, a subsequent RCT among women in Tanzania reported no effect of acyclovir 400 mg b.i.d. on genital HIV-1 RNA and HSV-2 DNA  at 6 or 12 months, whereas an RCT in Zimbabwe found no effect on genital HIV-1 RNA but an impact on genital HSV-2 DNA [odds ratio (OR), 0.24; 95% CI, 0.12–0.48] at 3 months . Possible explanations for the varied findings include different durations of follow-up, drug regimens and levels of adherence achieved within these high-risk study populations, with lower adherence reported in the Tanzanian and Zimbabwean trials. Our estimate of averting one infection by treating nine to 11 individuals, starting therapy halfway through asymptomatic infection, requires individuals to be treated for approximately 6 years, with adherence continuing at the high levels maintained in the trials, which could be challenging. However, suppressive therapy offers the additional benefits of reducing HSV-2 symptoms and would keep HIV-1-infected individuals within the healthcare system, allowing appropriate timing of HAART initiation, whereas loss of contact and delayed start of HAART would result in poorer prognoses.
Our analysis has a number of limitations. We assume that all partners of the participants are HIV-1 uninfected, so this will overestimate the impact of therapy. Transmission potential was derived from data from discordant couples, which may underestimate infectiousness relating to more casual partnerships. Transmission potential is estimated for a scenario assuming random mixing between partners, which corresponds to a very high partner change rate. Mixing is seldom random, yet random mixing may be more appropriate for estimating transmission potential for these high-risk women than the other extreme of serial monogamous partnerships. A sensitivity analysis exploring the impact of these assumptions shows that modelling serially monogamous relationships would avert fewer HIV-1 infections with suppressive therapy because the transmission potential of each woman is reduced (see document and figures, Supplemental Digital Content 1, 2 and 3).
We have made the simplifying assumption that by the end of each 3-month trial, the maximum impact of suppressive therapy has been reached, but there was a slight incremental benefit over time in Burkina Faso, which would increase the number of infections averted. However, such an effect may be mitigated if accompanied by waning adherence or if the effectiveness of HSV therapy actually decreases over time (there has been concern over the selection of resistant HIV-1 mutants under the selective pressure of acyclovir in vitro ).
A recent review of serodiscordant couple studies estimated that the probability of transmitting HIV-1 would increase by 20 and 40% for 0.3 and 0.5 log10 copies/ml increases in PVL, respectively, with a 25 and 44% increased risk of progression to AIDS or death . We believe that the estimated changes in infectiousness and duration of asymptomatic infection used in our analysis are more reliable because x units change in either of these parameters does not change linearly with y units of log10 PVL, as assumed in the review. Our estimates depend not only on the change in PVL but also on the original set-point because a small change in PVL when at high or low levels has less impact than at intermediate PVL (Fig. 1). However, for comparison, using a ‘typical’ viral set-point value of 4.5 log10 copies/ml (as used by others ) and formulas (1) and (2), infectiousness would increase by 18 and 26% and duration of infection before AIDS would decrease by 24 and 44% for 0.3 and 0.5 log10 copies/ml increases in PVL, respectively using our methods, yet these values change substantially for different baseline viral set-points.
Our analysis suggests that although in theory, interventions to reduce PVL could risk the unintended consequence of increasing rather than decreasing overall HIV-1 transmission; this is unlikely to occur among sub-Saharan African target populations. This is because the distribution of set-point PVL is sufficiently low that any reduction in PVL likely moves the population to a lower mean transmission potential. Although the benefits of HSV suppressive therapy as a public health measure are predicted as modest using standard regimens, investigating the effect of higher dosing schedules may be important. Delaying the need to initiate HAART would be of particular value in resource-limited settings, in which demand for HAART will likely continue to outstrip supply.
We thank T. Clayton [London School of Hygiene and Tropical Medicine (LSHTM)] for useful discussions and assistance. For the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 1285 study in Burkina Faso, we wish to thank the women and the organizations of persons living with HIV/AIDS who participated in this study (‘Yerelon’, ‘Espoir et Vie’, Centre 'Solidarité Action Sociale' and ‘Espoir pour Demain’) and staff at Service d'Hygiène, Bobo-Dioulasso and all ANRS1285 study staff listed below. For the South African study, we wish to thank the volunteers for their participation in the study, the study staff, Charlotte Ingram, Kirthi Hira and Ischelle Doddameade of Contract Laboratory Services (CLS) for testing of routine laboratory specimens and the City of Johannesburg Esselen Street Clinic staff; colleagues at LSHTM who provided statistical or analytical advice (Helen Weiss, Richard Hayes, Simon Cousens, Mike Kenward and Nicolas Nagot); and the trial Data Safety Monitoring Board (DSMB) (Chair: Andrew Nunn, MRC/CTU, UK, Rachel Jewkes, MRC, South Africa and Adrian Puren, National Institute of Communicable Diseases, South Africa). This work was supported by the Wellcome Trust [R.F. B. (GR082623MA)]. We thank the MRC for Centre funding.
R.F.B. conceived and cowrote the article with substantial inputs from T.D.H., R.C., C.F., A.C.G. and H.A.W. R.F.B. and J.T.G. conducted the statistical analysis. J.T.G., A.C.G., T.D.H., C.F. and H.A.W. advised on statistical analyses. A.C.G., T.D.H., R.F.B. and R.C. conceptualized and designed the schematic figures. All authors provided and contributed towards the analysis and interpretation of the data and to the development and critical revision of the manuscript, including principal investigators for each of the trial datasets used (N.N., S.D., P.M., F.D.W.) providing input based on their expertise and field experience. N.N. and P.M. were principal investigators of the ANRS1285 study in Burkina Faso, and H.A.W. was the study senior statistician; S.D. and P.M. were principal investigators of the Wellcome Trust trial in South Africa. All authors have seen and approved the submitted version of the manuscript.
This study was funded by the Wellcome Trust (GR082623MA), with Centre funding from the MRC. The ANRS1285 study in Burkina Faso was sponsored by France's Agence Nationale de Recherches sur le SIDA et les Hépatites (ANRS). The South African study was funded by the Wellcome Trust (GR074151MA), the South African National Research Foundation (TTK2005071300016) and the UK's Department for International Development (DFID)-funded Knowledge Programme on HIV/AIDS and Sexually Transmitted Infections of the LSHTM.
Study group: Investigators in the ANRS 1285 study group (Burkina Faso trial) were as follows: Centre Muraz, Bobo-Dioulasso, Burkina Faso: E. Bahembera, A. Berthé, M. Coulibaly, M.C. Defer, R. Diallo, D. Djagbaré, I. Konaté, F. Ky-Dama, G.T. M'Boutiki, N. Méda, I. Millogo, N. Nagot, A. Ouédraogo, D. Ouedraogo, F. Rouet, A. Sanon, H. Sawadogo, R. Vallo, L. Vergne (deceased January 2007); London School of Hygiene and Tropical Medicine, London, UK: P. Mayaud, N. Nagot, H.A. Weiss; Montpellier University Hospital and Research Unit 145, Institute for Research and Development and University of Montpellier 1, Montpellier, France: P. Becquart, V. Foulongne, M. Segondy, P. Van de Perre; University Hospital of Bobo-Dioulasso, Burkina Faso: J.B. Andonaba, A. Sawadogo. Investigators for the South African trial were as follows: University of Witwatersrand, Johannesburg, Republic of South Africa: S. Delany, N. Mlaba, G. Akpomiemie, J. Dhookie, H. Rees, A. Capovilla, W. Stevens; London School of Hygiene and Tropical Medicine, London, UK: T. Clayton, P. Mayaud; Laboratoire de Microbiologie, Hôpital Saint-Louis, Paris, France: J. Legoff; Université Paris V, Equipe « Immunité et Biothérapie Muqueuse », Unité INSERM Internationale U743 (« Immunologie Humaine »), Centres de Recherches Biomédicales des Cordeliers, & Laboratoire de Virologie, Hôpital Européen Georges Pompidou, Paris, France: L. Belec.
P. M. received limited funding from Glaxo SmithKline for previous research. The views expressed herein are those of the authors and do not necessarily reflect the official policy or position of DFID.
1. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73–83.
2. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004; 35:435–445.
3. McClelland RS, Wang CC, Overbaugh J, Richardson BA, Corey L, Ashley RL, et al. Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002; 16:2425–2430.
4. Freeman EE, Orroth KK, White RG, Glynn JR, Bakker R, Boily MC, et al. Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. Sex Transm Infect 2007; 83(Suppl 1):i17–i24.
5. Abu-Raddad LJ, Magaret AS, Celum C, Wald A, Longini IM Jr, Self SG, Corey L. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE 2008; 3:e2230.
6. Mbopi-Keou FX, Gresenguet G, Mayaud P, Weiss HA, Gopal R, Matta M, et al. Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: opportunities for intervention. J Infect Dis 2000; 182:1090–1096.
7. WHO. Herpes simplex virus type 2: programmatic and research priorities in developing countries. London, UK: Report of a WHO/UNAIDS/LSHTM workshop; 14–16 February 2001. WHO/HIV_AIDS/2001.05 ISBN 92-9173-144-7.
8. Delany S, Mlaba N, Clayton T, Akpomiemie G, Capovilla A, Legoff J, et al. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS 2009; 23:461–469.
9. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, Vergne L, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356:790–799.
10. Tanton C, Watson-Jones D, Rusizoka M, Le Goff J, Weiss H, Lefebvre C, et al. A randomized controlled trial in Tanzania to assess the impact of HSV2 suppressive therapy on genital HIV viral load among HSV2 and HIV1 seropositive women [abstract TUPEC011]. In: International AIDS Society Conference; 22–25 July 2007; Sydney, Australia.
11. Cowan FM, Pascoe S, Barlow K, Langhaug L, Jaffar S, Hargrove J, et al. A randomised placebo controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers. Sex Transm Infect 2008; 84:548–553.
12. Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006; 20:2305–2313.
13. Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Zuniga R, et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J Infect Dis 2007; 196:1500–1508.
14. Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis 2008; 198:1804–1808.
15. Dunne EF, Whitehead S, Sternberg M, Thepamnuay S, Leelawiwat W, McNicholl JM, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. J Acquir Immune Defic Syndr 2008; 49:77–83.
16. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001; 17:901–910.
17. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921–929.
18. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167–1170.
19. de Wolf F, Spijkerman I, Schellekens PT, Langendam M, Kuiken C, Bakker M, et al. AIDS prognosis based on HIV-1 RNA, CD4+ T-cell count and function: markers with reciprocal predictive value over time after seroconversion. AIDS 1997; 11:1799–1806.
20. Fraser C, Hollingsworth TD, Chapman R, de Wolf F, Hanage WP. Variation in HIV-1 set-point viral load: epidemiological analysis and an evolutionary hypothesis. Proc Natl Acad Sci U S A 2007; 104:17441–17446.
21. Efron B, Tibshirani R, editors. An introduction to the bootstrap. Florida: Chapman & Hall; 1998.
22. Donnelly CA, Bartley LM, Ghani AC, Le Fevre AM, Kwong GP, Cowling BJ, et al. Gender difference in HIV-1 RNA viral loads. HIV Med 2005; 6:170–178.
23. Napravnik S, Poole C, Thomas JC, Eron JJ Jr. Gender difference in HIV RNA levels: a meta-analysis of published studies. J Acquir Immune Defic Syndr 2002; 31:11–19.
24. Duffus WA, Mermin J, Bunnell R, Byers RH, Odongo G, Ekwaru P, Downing R. Chronic herpes simplex virus type-2 infection and HIV viral load. Int J STD AIDS 2005; 16:733–735.
25. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109–2119.
26. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560–1571.
27. Geskus RB, Prins M, Hubert JB, Miedema F, Berkhout B, Rouzioux C, et al. The HIV RNA setpoint theory revisited. Retrovirology 2007; 4:65.
28. Ioannidis JP, Collier AC, Cooper DA, Corey L, Fiddian AP, Gazzard BG, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 1998; 178:349–359.
29. McMahon MA, Siliciano JD, Lai J, Liu JO, Stivers JT, Siliciano RF, Kohli RM. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008; 283:31289–31293.
30. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 2008; 22:2179–2185.
31. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008; 372:314–320.
This article has been cited 1 time(s).
LancetDaily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trialLancet
acyclovir; HIV; herpes simplex virus type 2; suppressive therapy; transmission; valacyclovir; viral load
© 2009 Lippincott Williams & Wilkins, Inc.
Highlight selected keywords in the article text.